Bioscientia Institut FÜR Medizinische Diagnostik GMBH

Bioscientia Institut FÜR Medizinische Diagnostik GMBH, doing business as Bioscientia Medizin. Labor. Service., provides clinical reference laboratory testing services to U.S. military healthcare facilities in Europe as a prime contractor on full-and-open, non-set-aside delivery orders and IDIQs, with no subcontract activity. The vendor is a for-profit organization headquartered in Ingelheim am Rhein, Germany, operating under NAICS 621511 (Medical Laboratories) and PSC Q301 (Reference Laboratory Testing).

Bioscientia's federal footprint is heavily concentrated in military healthcare support at Landstuhl Regional Medical Center (LRMC) in Germany. The vendor's customer base is dominated by Department of Army Medical Command (7 awards, $2.7 million combined potential value), the Defense Health Agency (8 awards, $1.9 million), and the Department of the Air Force United States Air Forces in Europe-Air Forces Africa (35 awards, $1.7 million), accounting for 98% of combined potential value across the portfolio. The Army and Air Force agencies place numerous small orders for laboratory testing services; the Defense Health Agency drives higher per-order values. Bioscientia holds single-award IDIQs with the Defense Health Agency: one with a $690,476 ceiling awarded May 1, 2022 through April 2025 (now expired), and a successor contract with a $400,000 ceiling awarded May 1, 2025 through April 30, 2026. Representative work includes a $277,330 purchase order from the Defense Health Agency for local reference laboratory testing at LRMC with a May 1, 2026 award date and April 30, 2027 completion, a $205,428 delivery order from the same agency awarded November 1, 2024 for clinical reference laboratory testing services, and a $124,338 delivery order awarded May 1, 2025 against the newer IDIQ. All work specifies College of American Pathologists accreditation and comprehensive diagnostic capabilities spanning chemistry, hematology, immunology, microbiology, and molecular diagnostics, with turnaround times of 72 hours or less.

Activity has been sparse and sporadic—two awards in 2022, one in 2023, two in 2024, three in 2025, and one in 2026—with combined potential value of $7.2 million across 112 total awards (though obligated spend of $9.5 million exceeds potential value, indicating invoiced work across award cycles). Only one award with combined potential value of $277 thousand reaches ultimate completion inside the next twenty-four months. The vendor operates exclusively as a prime contractor with no recorded subcontract work; all task orders flow through its single-award IDIQs with the Defense Health Agency, which serves as the central vehicle for recurring, contract-year delivery orders to support U.S. military medical operations in Germany.